Min Li
Director/Board Member chez ADAGENE INC.
Profil
Min Li is the founder and current Chief Executive Officer & Director of SciNeuro Pharmaceuticals, which is founded in 2020.
He is currently an Independent Director at Adagene, Inc., an Independent Non-Executive Director at Novotech Health Holdings Ltd., and an Independent Non-Executive Director at Laekna, Inc. Dr. Li's former positions include Senior Vice President at GSK Plc from 2013 to 2019, Professor-Neuroscience at The Johns Hopkins University School of Medicine from 1993 to 2013, and Partner at Lilly Asia Ventures (Hongkong) from 2019 to 2020.
Dr. Li received his undergraduate degree from Wuhan University in 1984 and his doctorate from The Johns Hopkins University in 1991.
Postes actifs de Min Li
| Sociétés | Poste | Début |
|---|---|---|
| ADAGENE INC. | Director/Board Member | 08/02/2021 |
| LAEKNA, INC. | Director/Board Member | - |
Scineuro Pharmaceuticals
 Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then. | Founder | 01/01/2020 |
Novotech Health Holdings Ltd.
 Novotech Health Holdings Ltd. BiotechnologyHealth Technology Novotech Health Holdings Ltd. operates as a biotech-focused full-service contract research organization. Its integrated CRO platform provides clinical trial services ranging from consulting services prior to the commencement of the clinical phase to late-phase clinical trials. The firm’s services include: clinical trial services which include clinical research, bioequivalence and pharmacodynamics research, and drug development consulting services; and its related clinical trial services which include laboratory, site management organization, flexible insourcing and Phase I clinical trial unit services. The company was founded on February 25, 2020 and is headquartered in Singapore. | Director/Board Member | 01/05/2021 |
Anciens postes connus de Min Li
| Sociétés | Poste | Fin |
|---|---|---|
| Lilly Asia Ventures (Hongkong) | Corporate Officer/Principal | 01/01/2020 |
| GSK PLC | Corporate Officer/Principal | 01/03/2019 |
| The Johns Hopkins University School of Medicine | Corporate Officer/Principal | 01/01/2013 |
Formation de Min Li
| Wuhan University | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GSK PLC | Health Technology |
| ADAGENE INC. | Health Technology |
| LAEKNA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Lilly Asia Ventures (Hongkong) | |
Scineuro Pharmaceuticals
Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then. | Health Technology |
Novotech Health Holdings Ltd.
Novotech Health Holdings Ltd. BiotechnologyHealth Technology Novotech Health Holdings Ltd. operates as a biotech-focused full-service contract research organization. Its integrated CRO platform provides clinical trial services ranging from consulting services prior to the commencement of the clinical phase to late-phase clinical trials. The firm’s services include: clinical trial services which include clinical research, bioequivalence and pharmacodynamics research, and drug development consulting services; and its related clinical trial services which include laboratory, site management organization, flexible insourcing and Phase I clinical trial unit services. The company was founded on February 25, 2020 and is headquartered in Singapore. | Health Technology |
